1
Exhibit 10.17
CLINICAL TRIAL AGREEMENT
This Agreement is entered into on _______________, 1999, by and between
VaxGen, Inc., 0000 Xxxxxx Xxxxxxxxx, Xxxxxxxx, Xxxxxxxxxx 00000, a Delaware
Corporation ("VaxGen"), and ________________________________________,
________________________________________, a
_______________ corporation (the "Study Center").
WITNESSETH
WHEREAS, VaxGen will supply specified funds and Investigational New Drug,
AIDSVAX(TM), to Study Center for a clinical trial which will be conducted under
the oversight and in the clinic of Investigator;
WHEREAS, this is a double-blind, placebo-controlled, registrational clinical
trial, and the results of this trial will be submitted for review and approval
by the U.S. Food and Drug Administration;
WHEREAS, VaxGen has developed the Investigational New Drug (as hereinafter
defined) as a vaccine for the prevention of HIV;
WHEREAS, in order to comply with certain regulatory approval obligations, VaxGen
intends to conduct a multi-center clinical trial with respect to the
Investigational New Drug, of which the Study (as hereinafter defined) is a part;
WHEREAS, the Study Center is qualified to perform the Study and such performance
would further the Study Center's instructional and research objectives;
WHEREAS, VaxGen desires the Study Center to perform, and the Study Center
desires to so perform, the Study on the terms set forth herein;
NOW THEREFORE, in consideration of the promises and the mutual covenants and
conditions hereinafter recited, the parties do hereby agree as follows:
1.0 DEFINITIONS.
For purposes of this Agreement:
1.1 "CFR" means the United States Code of Federal Regulations.
1.2 "CRFs" means "Case Report Forms" as that term is defined in the
Protocol.
1.3 "Confidential Information" has the meaning set forth in Section
10.2.
1.4 "Discoveries" has the meaning set forth in Section 13.1.
1.5 "Effective Period" has the meaning set forth in Section 2.3.
1.6 "FDA" means the United States Food and Drug Administration.
2
1.7 "HIV Laws" has the meaning set forth in Section 8.2.
1.8 "Informed Consent" has the meaning set forth in Section 5.1.
1.9 "Informed Consent Forms" has the meaning set forth in Section 5.1.
1.10 "Investigational New Drug" means "AIDSVAX(TM)", a vaccine
consisting of one or more gp120 antigens plus the adjuvant alum or placebo
containing adjuvant alum.
1.11 "Investigator" means the Principal Investigator, who is the real
person expressly engaged to directly perform or supervise the Study.
1.12 "Investigator Brochure" means the written document summarizing the
manufacturing, preclinical and clinical testing pertaining to the
Investigational New Drug.
1.13 "IRB" means the Study Center's Institutional Review Board.
1.14 "Protocol" has the meaning set forth in Section 2.1.
1.15 "Researchers" means the Investigator and any real persons who
shall, under the supervision of the Investigator or the Study Center, assist the
Study Center and the Investigator in performing the Study in accordance with
this Agreement.
1.16 "Rights" has the meaning set forth in Section 13.1.
1.17 "Study" means the clinical research trial to be performed by the
Investigator and any other Researchers at the Study Center in accordance with
this Agreement and the Protocol.
1.18 "Subject" means a human being who participates in the Study.
1.19 "VaxGen Property" means all property in which VaxGen has a
proprietary interest, including, but not limited to, (1) the Confidential
Information; (2) the Discoveries; (3) statistical data, evaluations, analyses
and specimens generated or collected by the Study Center in connection with the
conduct of the Study; (4) any quantities of the Investigational New Drug; (5)
the Protocol; (6) the Investigator Brochure; (7) CRFs and Informed Consent
Forms, whether or not completed; and (8) slides, study notes and other
documents, research supplies and any other related materials that are furnished
to the Study Center or the Researchers by or on behalf of VaxGen.
2.0 STUDY PERFORMANCE.
2.1 The Study shall be performed by the Study Center in accordance with
Protocol Number VAX 004 entitled "A Phase Ill Trial to Determine the Efficacy of
AIDSVAX(TM) B/B Vaccine in Adults at Risk of Sexually Transmitted HIV-1
Infection in the United States," attached hereto as Exhibit A, and any
subsequent amendments made thereto in accordance with Article 16.0 (the
"Protocol"). The Protocol is subject to approval by the IRB. The Informed
2
3
Consent is subject to approval by VaxGen and the IRB. Any statement in the
Protocol that is inconsistent with this Agreement shall be superseded by this
Agreement.
2.2 The Study Center's Investigator shall be ____________________, M.D.
The Investigator shall be responsible, either directly or through other
Researchers, for the performance of the Study in accordance with the highest
standards of medical and clinical research practice. If for any reason the
Investigator is unable to continue to serve as Investigator and a successor,
acceptable to both the Study Center and VaxGen, is not available, this Agreement
shall be terminated as provided by Section 14.2.
2.3 The Study Center acknowledges that, with respect to the performance
of the Study, time is of the essence. The effective period of this Agreement
will commence on _______________, 1999 and shall expire on September 30, 2002
(the "Effective Period"). In the event that the Study Center does not fulfill
its obligations under this Agreement with respect to the Study during the
Effective Period, VaxGen may, at its sole option, extend the Effective Period by
one-month periods.
2.4 The Study Center shall enroll one hundred fifty (150) Subjects in
the Study. The Study Center shall use its best efforts to complete Subject
enrollment by February 28, 1999. In the event the Study Center is unable to
complete the enrollment by such date, VaxGen may reassign the Study Center's
enrollment slots, thereby reducing the number of Subjects the Study Center may
enroll in the Study. The Study Center acknowledges that the Study is part of a
multi-center clinical trial. When the enrollment goal of 5,000 subjects for the
clinical trial as a whole is reached, enrollment will be closed at all sites,
including the Study Center, regardless of whether the Study Center or any other
site has reached its individual enrollment goal.
2.5 The Study Center shall utilize the following clinical facilities for
the conduct of the Study: _________________________.
3.0 PAYMENT AND PAYMENT SCHEDULE.
3.1 As consideration for performance under the terms of this Agreement,
VaxGen shall pay the Study Center according to the Clinical Study Payment
Schedule attached hereto as Exhibit B. All payments outlined on Exhibit B shall
remain firm for the duration of the Study, unless otherwise agreed in writing by
the Study Center and VaxGen. Such payments are inclusive of all associated
costs, fees and charges, including any relevant or applicable overheads due any
party, entity or institution.
3.2 Payments made pursuant to this Article 3.0 shall be paid to the
Study Center, entity ____________________ (TAX ID) and sent to the following
address:
Name
Entity
Address
City, State ZIP
3.3 Payment as set forth in this Section 3 shall constitute full payment
for the Study and VaxGen shall have no other payment obligations hereunder.
3
4
4.0 INVESTIGATIONAL NEW DRUG AND SPECIMENS.
4.1 VaxGen shall provide the Study Center with the Investigational New
Drug to be used solely for purposes of the performance of the Study by the Study
Center. The Study Center agrees to limit access to the Investigational New Drug
to only those individuals engaged in conducting [or participating in] the Study.
The Study Center shall not transfer the Investigational New Drug to any third
party. The Study Center shall maintain complete and accurate records of all
quantities of Investigational New Drug received and dispersed by the Study
Center, as indicated in Section 6.2 below.
4.2 The Investigational New Drug shall be shipped to the Study Center in
containers marked in accordance with 21 C.F.R Section 312.6. All used containers
of the Investigational New Drug shall be destroyed or otherwise disposed of in
accordance with the Study Center's Standard Operating Procedures. Written
certification of such destruction or disposal shall be provided to VaxGen by the
Study Center. All expired or unused Investigational New Drug shall be returned
to VaxGen at the completion of the Study or termination of this Agreement,
whichever occurs first.
4.3 The Study Center shall not collect specimens or use the
Investigational New Drug for use in any research without the prior written
permission of VaxGen. All specimens collected by the Study Center shall be
delivered to VaxGen by the Study Center in a timely manner throughout the
performance of this Study in accordance with the Protocol or as otherwise
provided by VaxGen, and in no event later than five (5) working days after the
date of termination of this Agreement or on which VaxGen otherwise requests
delivery of the specimens.
5.0 SUBJECTS.
5.1 Informed consent of each of the Subjects participating in the Study
shall be obtained in accordance with 21 C.F.R. Sections 50 and 56, including
completion of the VaxGen-approved Informed Consent Form, which has been approved
by the IRB (such activities to be referred to collectively as "Informed
Consent"). The Study Center shall administer the Investigational New Drug only
to Subjects from whom Informed Consent has been properly obtained by the Study
Center under this Section 5.0. The Study Center shall maintain adequate
documentation of its obtainment of the Informed Consent of each Subject.
5.2 The Study Center shall monitor the Subjects in accordance with the
Protocol. The Study Center shall require the Investigator to promptly report to
VaxGen all serious adverse experiences that may be associated with the
administration of the Investigational New Drug that occur during the course of
the Study. For purposes of this Section, "promptly" shall mean within
twenty-four (24) hours of the occurrence of any such serious adverse experience.
Failure to comply with this Section shall constitute reasonable grounds for
VaxGen to terminate this Agreement as provided in Section 14.2.
5.3 VaxGen agrees to assume responsibility for the direct reasonable and
necessary costs of treatment of any adverse reaction or injury to a Subject that
is a vaccine induced reaction to the Investigational New Drug that has been
administered in accordance with this Agreement, the Protocol and any other
written instructions of VaxGen, and are in no way attributable to the
4
5
negligence or misconduct of any agent or employee of the Study Center. VaxGen
shall not be responsible for costs incurred for the treatment of HIV-1
infection.
5.4 VaxGen, the Study Center and the Researchers shall hold in
confidence the identity of the Subjects and shall comply with all applicable
laws regarding the confidentiality of their identities and their individual
medical records.
6.0 RECORDKEEPING, REPORTING AND ACCESS TO RECORDS.
6.1 VaxGen or its authorized representatives, and regulatory authorities
to the extent permitted by law, may, during regular business hours:
(1) Examine and inspect the Study Center's facilities used in
performance of the Study, including storage or use of the Investigational New
Drug;
(2) Observe conduct of the Study;
(3) Inspect and copy all data and work products relating to the
Study or the IRB, including CRFs, Subject medical records and Informed Consent
Forms and other Informed Consent documentation, required licenses, certificates
and accreditation; and
(4) Interview the Investigator, other Researchers and Study
Center or IRB personnel.
The Study Center shall, and shall cause the Investigator and any other
Researcher to, cooperate with any such inspection and shall ensure timely access
to requested records and data.
6.2 The Study Center, including the Investigator and any other
Researchers, shall perform the recordkeeping and reporting obligations described
in the Protocol and this Agreement and shall do so in accordance with all
applicable local, State and federal laws, regulations and guidelines. Such
recordkeeping shall be complete, current, accurate, organized and legible, and
shall be performed in a manner acceptable for the collection of data for
submission to, or review by, the FDA and in full compliance with such laws,
regulations, guidelines and in full compliance with the Protocol. These
recordkeeping and reporting obligations include, but are not limited to, the
following:
(1) maintaining written records, accounts, notes, reports and data relating to
the Study, including full case histories, as described in 21 CFR Section 312.62;
(2) completing original, authorized Informed Consent Forms and CRFs for each
Subject on a per visit basis; (3) maintaining adequate documentation of the
obtainment of Informed Consent from each Subject; (4) preparing and submitting
all safety, progress, interim and final reports; (5) maintaining records of the
receipt, use and disposition of the Investigational New Drug; (6) maintaining
copies of all correspondence with VaxGen, the IRB and the FDA; and (7)
maintaining other documents indicated by the Protocol or specified by VaxGen.
All such records shall be submitted to VaxGen upon request or upon completion of
the Study or as otherwise directed by VaxGen. All reports provided to VaxGen by
the Study Center must be in accordance with the Protocol and FDA requirements or
as otherwise instructed by VaxGen. Notwithstanding the foregoing, Study Center
may retain one copy of the records for archival purposes.
5
6
6.3 The Study Center agrees to maintain all records required by this
Agreement and resulting from the Study for the time required by applicable
Federal, State and local laws and regulations and shall allow for inspections of
all such records by VaxGen or its authorized representatives during such period
of retention.
7.0 FDA ASSISTANCE.
7.1 At the request and expense of VaxGen, the Study Center shall, and
shall cause the Investigator to:
(1) assist VaxGen in the preparation and submission of
investigational new drug applications, and any other premarket applications
relating to the Study as may be required by the FDA; and
(2) attend meetings with the FDA and other regulatory agencies
regarding such applications and the associated approvals as requested by VaxGen.
7.2 The Study Center shall promptly inform VaxGen of any effort or
request by the FDA or other persons to contact the Study Center, the
Investigator or any other Researcher regarding the Study. The Study Center shall
promptly notify VaxGen in the event that the FDA or any other governmental
agency, either state or federal, issues the Study Center, the IRB, the
Investigator or any other Researcher any Notice of Inspectional Observations,
Warning Letters or other comparable documents citing allegedly improper or
inadequate research practices with respect to any activity of the Study Center,
the Investigator, other Researchers or the IRB. For purposes of this section,
"promptly" shall mean within three (3) business days of the receipt of any such
documents, efforts or requests by the Study Center, the Investigator or any
other Researcher.
8.0 COMPLIANCE WITH STATUTES.
8.1 The Study Center shall ensure that the Study is performed in
conformance with the standards of Good Clinical Practice acceptable to the FDA,
with the Protocol and other Written instructions provided by VaxGen, and with
all applicable local, State and Federal laws, regulations and guidelines,
including, but not limited to 21 CFR parts 312, 50 and 56.
8.2 In connection with any testing or other activity undertaken pursuant
to the Study with respect to determining the human immunodeficiency virus (HIV)
status of any Subject or potential Subject, the Study Center agrees to assume
full responsibility for complying with all federal, State, and local laws,
rules, and regulations as amended from time to time, directed to the HIV status
of individuals (collectively, "HIV Laws"), including, without limitation, HIV
Laws covering informed consent, screening, testing, counseling, reporting,
confidentiality, disclosure and record keeping.
9.0 WARRANTIES.
9.1 The Study Center warrants that the Study Center, the Investigator
and each of the other Researchers have all training, information, licenses,
approvals or certifications necessary for safely, adequately and lawfully
performing the Study, and the Study Center shall ensure that all such
6
7
training, licenses, approvals or certifications are properly maintained
throughout the course of the Study. The Study Center further warrants to the
best of its knowledge that it, the Investigator and the other Researchers are
not subject to any conflicting obligation or legal impediment that might
interfere with the performance of the Study or that might impair the acceptance
of data resulting from the Study by the FDA, and that no such obligations or
conflicts will be incurred or permitted in the future without the prior written
approval of VaxGen.
9.2 The Study Center warrants that none of the Study Center, the
Investigator or the other Researchers have been or may be subject to debarment
under the provisions of the Generic Drug Enforcement Act of 1992, 21 U.S.C.
306(a) or (b), or have otherwise been disqualified or suspended from performing
the Study or otherwise subject to any restrictions or sanctions by the FDA or
any other governmental agency or professional body with respect to the
performance of scientific or clinical investigations. In the event that the
Study Center or any of the Researchers (1) becomes debarred; or (2) receives
notice of action or threat of action with respect to such debarment during the
term of this Agreement, the Study Center shall notify VaxGen immediately. In the
event that the Study Center or any of the Researchers become debarred during the
term of this Agreement, or the Study Center receives notice of any action or
threat of action as set forth in clause (2), VaxGen may, at its sole option,
automatically terminate the Agreement without any further action or notice by
either party.
9.3 The Study Center hereby certifies that it has not and will not use
in any capacity the services of any individual, corporation, partnership, or
association which has been debarred under 21 U.S.C. 306(a) or (b). In the event
that Study Center becomes aware of the debarment or threatened debarment of any
individual, corporation, partnership, or association providing services to Study
Center which directly or indirectly relate to Study Center's activities under
this Agreement, Study Center shall notify VaxGen immediately. VaxGen shall have
the right to terminate this Agreement immediately upon receipt of such notice.
9.4 The Study Center warrants that the Investigator or other Researchers
has not entered, and will not enter, into any contractual agreement or
relationship that would in any way conflict with or compromise any VaxGen
Property at the time of the execution of this Agreement or arising out of or
related to the performance thereunder.
9.5 The Investigational New Drug provided under this Agreement is not
for commercial use. VaxGen makes no representations or warranties, express or
implied, related to the Investigational New Drug, including without limitation
any warranty of merchantability or fitness for a particular purpose, or that the
use of the Investigational New Drug for purposes other than specified in this
Agreement will not infringe any patent or other proprietary right.
9.6 Any specimens collected by the Study Center and provided to VaxGen
in accordance with this Agreement shall be "as is" and the Study Center makes no
representation or warranty (express or implied) that the specimens are free from
harmful biological or infectious agents or organisms and are otherwise
merchantable or fit for a particular purpose or use.
10.0 CONFIDENTIALITY; PROTECTION OF VAXGEN PROPERTY.
10.1 The Study Center agrees that the Study Center and the Researchers
shall protect
7
8
VaxGen Property from unauthorized use, access, duplication, disclosure, loss or
damage. In protecting VaxGen Property, the Study Center will take adequate
measures, including but not limited to the following: (1) limit access and use
of VaxGen Property to authorized Researchers for whom such access and use are
required for performance of the Study; (2) use VaxGen Property only for the
purposes described in the Protocol or other purposes as approved by VaxGen in
writing; (3) prevent transfer or disclosure of VaxGen Property to any other
person or entity without VaxGen's written approval; (4) prevent any unauthorized
duplication of VaxGen Property in written or electronic form and any
decompilation or modification of the Investigational New Drug; (5) use at least
the same degree of care and discretion it uses in maintaining the
confidentiality of its own Confidential Information; (6) upon completion or
termination of the Study, or on VaxGen's written request, return to VaxGen all
VaxGen Property and all written material that incorporates any VaxGen Property
and, if so requested, provide a written inventory showing the disposition of all
VaxGen Property received or developed by the Investigator. Return of VaxGen
Property shall include permanent removal of all VaxGen Property from all
computer or other electronic storage media that is not returned to VaxGen,
except as otherwise required by the FDA and/or local, state and federal laws,
regulations and guidelines or other governmental agencies.
10.2 The Study Center shall not, and shall obligate the Researchers not
to, disclose or use for any purpose other than performance of the Study, any
trade secret, privileged record or other confidential or proprietary information
(collectively, the "Confidential Information") disclosed to or developed by the
Study Center pursuant to this Agreement. Such Confidential Information includes
but is not limited to all information received by the Study Center or the
Investigator from VaxGen, the Investigator Brochure and the Protocol, the
Investigational New Drug and all information related to the Investigational New
Drug, all information developed during the Study, the CRFs and safety and
efficacy information, all data, results, reports, technical and economic
information, the existence or terms of this or other research agreements with
VaxGen, commercialization and research strategies, trade secrets and know-how
disclosed by VaxGen to the Study Center or any Researcher directly or
indirectly, whether in writing or orally, or developed under this Agreement.
Such Confidential Information shall be disclosed to the Study Center by VaxGen
hereunder in writing or if disclosed orally or in other than documentary form,
shall be reduced to writing within 30 days thereafter. Confidential Information
that is not in oral or written form, such as, but not limited to data tapes,
shall be designated in writing as confidential within thirty (30) days after
disclosure. The obligation of non-disclosure shall not apply to information
that:
(1) was known to Study Center or the Investigator, as evidenced
by prior written records, prior to receiving such information either directly or
indirectly from VaxGen, or
(2) is generally known to the public or that becomes generally
known to the public through no act or omission on the part of the Study Center
or the Investigator, or
(3) is disclosed to the Study Center or the Investigator on a
non-confidential basis at any time by a third party who has not obtained or
disclosed such information through improper or unlawful means.
10.3 The Study is intended to be conducted as a blind trial. The Study
Center shall not perform any independent assays for the purpose of unblinding
treatment assignment.
8
9
10.4 In the event the Study Center or the Investigator is ordered to
provide Confidential Information by a lawful judicial or government order, the
Study Center shall promptly inform VaxGen and shall permit VaxGen to defend
against such order of disclosure and shall assist in such defense to the extent
permitted by law. In no other circumstances may the Study Center or the
Investigator disclose information without the consultation and prior written
consent of VaxGen.
11.0 PUBLICATION AND ADVERTISING.
11.1 The Study is being conducted as part of a multi-center clinical
trial. As stipulated in the Protocol, data from all such centers shall be pooled
and analyzed for publication in a final report (Primary Publication). Study
Center agrees that the Primary Publication to be coordinated by VaxGen will be
the first publication to present the pooled Study results.
Following the Primary Publication, or if the Primary Publication is not
published within one year of termination of this Agreement, the Study Center and
the Investigator shall have the right and be encouraged to publish or present
materials related to the Study. At least thirty (30) days prior to submission of
any material for publication or presentation by the Study Center or the
Investigator, the Study Center shall provide VaxGen with such material for its
review and comment. Expedited reviews of such materials may be arranged at
VaxGen's sole option. If requested in writing by VaxGen, the Study Center shall
withhold, or shall cause the Investigator to withhold, material from submission
for publication or presentation an additional sixty (60) days to allow for the
filing of a patent application, or the taking of such measures as VaxGen deems
appropriate, to establish and preserve its proprietary rights in the information
in the material being submitted for publication.
11.2 In the event VaxGen permits Study Center to conduct ancillary
research as provided in Section 4.3, Study Center and Investigator shall not
publish or make presentations with respect to the ancillary research until after
the primary data obtained from conducting this Study is published or publicly
presented.
11.3 VaxGen and the Study Center shall obtain prior written permission
from the other before using the name, insignia, symbol(s), trademarks or
logotypes associated with such party in any form of publicity in connection with
the Study; provided however that VaxGen may use the name associated with the
Study Center, or the names of the Researchers and Study Center employees to
identify the Study Center as the site at which the Study was conducted and to
identify those individuals responsible for conducting the Study. The disclosure
restrictions contained in this Section shall not apply to the extent such
disclosure is legally required.
11.4 VaxGen shall not use, nor authorize others to use, the name,
insignia, symbol(s), trademarks or logotypes of the Study Center or the
Researchers in any advertising, promotional or publicity material or make any
form of representation or statement in relation to the Study that would
constitute any express or implied endorsement by the Study Center of the
Investigational New Drug without prior written approval of the Study Center or
the Researchers.
11.5 Nothing contained herein shall prevent immediate public disclosure
of results by the Study Center or the Investigator to the extent necessary to
prevent or mitigate a serious health hazard.
9
10
12.0 INDEMNIFICATION; LITIGATION.
12.1 VaxGen agrees to indemnify, and hold harmless the Study Center, its
officers, agents and employees, and each of the Researchers from any and all
liability, loss (including attorney's fees), or damage they may suffer as the
result of claims, demands, or judgments for bodily injury or death of a Subject
caused by the use of the Investigational New Drug during the course of the
Study, provided that:
(1) The Study was conducted in accordance with this Agreement,
the Protocol and all written instructions of VaxGen concerning the Study;
(2) Such claims, demands or judgments do not arise, in whole or
in part, from the negligent or willful acts or omissions or any misuse of the
Investigational New Drug by the Indemnitee, the Investigator or any other
Researcher or by any other person on the Study Center's property, exclusive of
VaxGen's employees;
(3) The Study was conducted in accordance with all applicable
federal, state or local laws, regulations and guidelines, including all HIV
Laws, and in conformance with the practices of reasonable and prudent clinical
investigators, physicians and medical institutions.
12.2 In the event that a claim or action is or may be asserted, the
Study Center shall have the right to select and obtain representation by
separate legal counsel. If the Study Center exercises such right, all costs and
expenses incurred by the Study Center for such separate counsel shall be borne
by the Study Center.
12.3 The Study Center agrees to indemnify and hold VaxGen harmless from
any and all liability, loss (including attorneys' fees), or damage it may suffer
as the result of claims, demands, or judgments which are, or are alleged to be,
arising out of:
(1) a failure to adhere to the terms of this Agreement, the
Protocol, any other written instruction of VaxGen;
(2) negligent or willful acts or omissions or any misuse of the
Investigational New Drug by the Study Center, the Investigator or any other
Researcher or by any other person on the Study Center's property, exclusive of
VaxGen's employees; or
(3) a breach of any applicable federal, state, or local laws,
regulations, or guidelines, including any HIV Laws, by the Study Center, the
Investigator or any other Researcher.
12.4 Each Party's agreement to indemnify and hold the other harmless is
conditioned on the indemnified party (i) providing written notice to the
indemnifying party of any claim, demand or action arising out of the indemnified
activities within ten (10) days after the indemnified party has knowledge of
such claim, demand or action, (ii) permitting the indemnifying party to assume
full responsibility to investigate, prepare for and defend against any such
claim or demand, (iii) assisting the indemnifying party, at the indemnifying
party's reasonable expense, in the investigation of, preparation for and defense
of any such claim or demand, and (iv) not compromising or settling such claim or
demand without the indemnifying party's written consent.
10
11
12.5 VaxGen agrees to assume the risk of all liability in connection
with its use of any specimens delivered to it by the Study Center in connection
with the Study and, further agrees to indemnify, defend and hold Study Center,
its agents and employees harmless (including reasonable attorney's fees) arising
as a result of any injury or damages relating to the shipment, handling, use, or
subsequent transfer of the specimens by VaxGen, its agents and employees.
12.6 Regardless of whether indemnification is sought under this Section
12.0, the Study Center shall inform VaxGen of any allegation or threat of legal
action that it receives pertaining to the Study.
12.7 Unless the Study Center is self-insured or unless other terms of
insurance are required by law, the Study Center shall maintain during the
performance of this Agreement [and for three (3) years after the termination of
this Agreement], Commercial General Liability Insurance, including Products and
Professional Liability coverage, in amounts not less than $1,000,000 per
occurrence and $1,000,000 per accident for bodily injury and death and property
damage liability insurance with limits of not less than $1,000,000 per
occurrence and $1,000,000 per accident. Such insurance policies shall be issued
by insurers having an A.M. Best rating of at least A-VIII or be otherwise
acceptable to VaxGen. Upon request, the Study Center shall provide satisfactory
evidence of its insurance or self-insurance and unless the Study Center is
self-insured, shall provide to VaxGen thirty (30) days prior written notice of
any cancellation in its coverage. If other insurance is required by law, the
Study Center shall inform VaxGen of such legal requirements and shall certify in
writing that it complies with these requirements.
13.0 INVENTIONS AND DATA.
13.1 VaxGen shall exclusively own all rights, title and interests
(collectively "Rights") in and to any inventions, data (including Study results
and any clinical specimens or samples obtained from Subjects), discoveries,
know-how, patents, copyrights, moral rights, trade and service marks, and trade
secrets and other intellectual property, including but not limited to
inventions, discoveries and technology relating to the Investigational New Drug
or otherwise generated by the Study (collectively, the "Discoveries"). The Study
Center and the Researchers hereby irrevocably transfer and assign any and all
their Rights in any such Discoveries to VaxGen. The Discoveries will be the sole
property of VaxGen and VaxGen will have the right to determine the treatment of
any Discoveries, including the right to keep them as trade secrets, to file and
execute patent applications on it, to use and disclose it without prior patent
application, to file copyright and trademark applications on it or its own name,
or to follow any other procedure VaxGen deems appropriate.
13.2 The Study Center and the Researchers agree: (1) to disclose
promptly in writing to VaxGen all Discoveries including but not limited to the
surrender of all original lab books and other records; (2) to cooperate with and
assist VaxGen to apply for and to execute applications, assignments, affidavits,
or other documents, reasonably necessary to obtain any patent, copyright,
trademark or other statutory or other protection for Discoveries in VaxGen's
name as VaxGen deems appropriate; and (3) to otherwise treat all Discoveries as
Confidential Information.
13.3 Neither the Investigator nor the Study Center, including its
employees or agents, shall acquire any rights of any kind whatsoever with
respect to the Investigational New Drug as a
11
12
result of performance under this Agreement or otherwise.
14.0 TERMINATION.
14.1 This Agreement may be terminated or suspended before the expiration
of the Effective Period by the mutual written consent of the parties.
14.2 This Agreement may be terminated or suspended by either party upon
immediate prior notice to the others if any of the following conditions occur:
(1) The authorization and approval to perform the Study in the
United States is permanently withdrawn by the FDA or the IRB or any other lawful
authority or authorization and is not restored within three months of
suspension.
(2) VaxGen deems termination appropriate upon reasonable grounds.
(3) The Investigator is unable to continue and an acceptable
successor is not agreed upon.
14.3 In the event this Agreement is terminated for any reason prior to
expiration of the Performance Period, the Study Center shall take all reasonable
steps required by VaxGen, including communicating with the Subjects, to
facilitate completion of the Study at an alternative clinical site designated by
VaxGen. In such event, VaxGen will reimburse Study Center for its reasonable
direct costs incurred in connection with such transfer, as well as for
reasonable non-reimbursed costs incurred and non-cancelable commitments made
prior to the receipt by the Study Center that the Agreement will be terminated.
14.4 Termination of this Agreement by either party shall not affect the
rights and obligations of the parties that have accrued prior to the effective
date of the termination.
15.0 CONFLICT OF INTEREST.
In order to avoid the potential for conflicts of interest as well as the
appearance of such, the Study Center agrees that the Investigator, during the
term of this Agreement, shall not hold any financial interest in VaxGen,
including but not limited to shares of stock of VaxGen or options to purchase
shares of stock of VaxGen, without the prior written consent of VaxGen, and that
the Investigator shall not purchase or sell, whether for his own account or the
account of any other person or entity, shares of VaxGen stock. The Study Center
shall ensure that the Investigator makes all other Researchers aware of this
provision and shall make such provision fully applicable to them.
16.0 CHANGES TO PROTOCOL.
If at a future date changes to the Protocol are desired, such changes
shall be made through prior written agreement between VaxGen and the Study
Center. If such changes affect the cost of the performance of the Study by the
Study Center, the Study Center shall submit a written estimate of such cost to
VaxGen for prior approval. If in the course of performing this Agreement,
however, generally accepted standards of clinical research and medical practice
affecting the safety of the
12
13
Subjects require a deviation from the Protocol, such standards shall be
followed. In such case, the party aware of a need for a deviation shall
immediately inform the other party of the facts necessitating the deviation. Any
such changes or deviation from the Protocol shall be made in full compliance
with all applicable laws, regulations and guidelines.
17.0 GENERAL PROVISIONS.
17.1 Entire Agreement.
This Agreement represents the entire understanding as of the date hereof
between the parties with respect to the subject matter hereof, and supersedes
all prior agreements, negotiations, understandings, representations, statements,
and writings between the parties relating thereto. No modification, alteration,
wavier, or change in any of the terms of this Agreement shall be valid or
binding upon the parties hereto unless made in writing and duly executed by each
of the parties hereto.
17.2 Headings.
Article and section headings contained in this Agreement are included
for convenience only and form no part of the agreement between the parties.
17.3 Assignment.
(1) Study Center shall not assign this Agreement in whole or in
part to any other party and shall not appoint any other person as Investigator
without VaxGen's written consent. VaxGen may assign this Agreement in whole or
in part to any corporate parent, affiliate or subsidiary of VaxGen without Study
Center's consent.
(2) The Agreement shall inure to the benefit of, and be binding
upon, each party signatory hereto, its successors and permitted assigns. No
assignment shall relieve either party of the performance of any accrued
obligation which such party may at the time of assignment have under this
Agreement.
17.4 Independent Contractors.
The Study Center, including its agents and employees, shall be an
independent contractor at all times, and shall not be an agent of VaxGen and
shall have no actual, apparent or implied authority to bind VaxGen in any manner
or to any obligation whatsoever. The Investigator and the other Researchers
shall not be deemed to be employees of VaxGen and shall not be entitled to any
benefits available to employees of VaxGen.
17.5 Governing Law.
This Agreement is governed by the laws of the State of _______________,
not withstanding _______________'s, or any other jurisdiction's, choice of law
principles.
13
14
17.6 Notices.
All notices or other communications that are required or permitted
hereunder shall be in writing and sufficient if delivered personally, sent by
prepaid air courier, sent by mail, or sent by facsimile transmission, to the
address set forth below or such other address as is subsequently specified in
writing:
Study Center: VaxGen, Inc.:
Name Xxxxxx X. Xxxxxxxx
Title Administrator, Contracts and Budgets
Study Center VaxGen, Inc.
Address 0000 Xxxxxx Xxxx.
Xxxx, Xxxxx XXX Xxxxxxxx, XX 00000
000-000-0000 Telephone 000-000-0000 Telephone
000-000-0000 Facsimile 000-000-0000 Facsimile
Any such communication shall be deemed to have been given when delivered
if personally delivered, on the business day after dispatch if sent by air
courier, on the third business day following the date of mailing if sent by
mall; and on the date of facsimile transmission if sent by facsimile
transmission or electronic mail.
17.7 Severability.
If any one or more of the provisions of this Agreement shall be held to
be invalid, illegal or unenforceable, the validity, legality or enforceability
of the remaining provisions of this Agreement shall not in any way be affected
or impaired thereby.
17.8 Waiver.
The failure of any party hereto to insist upon strict performance of any
provision of this Agreement or to exercise any right hereunder will not
constitute a waiver of that provision or right.
17.9 Survival.
The rights and duties under Sections 1, 4.2, 5.3, 5.4, 7, 8, 9, 10, 11,
12, 13 and 17 shall survive the termination or expiration of this Agreement.
17.10 Integration.
Any Exhibits to this Agreement are incorporated into and made part of
this Agreement by reference.
14
15
The persons executing this Agreement represent and warrant that they
have the full power and authority to enter into this Agreement on behalf of the
persons or entities for whom they are signing.
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed in duplicate counterpart original by their duly authorized
representatives to be effective as of the date of this Agreement.
Study Center: VaxGen, Inc.:
By: By:
------------------------------------- ---------------------------------
Print Name: Print Name: Xxxxxx X. Xxxxxxx, M.D.
---------------------------- ------------------------
Title: Title: President
---------------------------------- ------------------------------
Date: Date:
----------------------------------- ------------------------------
I, ____________________, M.D., named as Investigator in this Agreement,
acknowledge that I have read this Agreement in its entirety and that I have
reviewed the obligations the Study Center has undertaken on my behalf. I agree
to use best efforts to assist the Study Center in meeting those obligations.
Investigator:
By:
-------------------------------------
Print Name:
-----------------------------
Title: Principal Investigator
----------------------------------
Date:
----------------------------------
15
16
EXHIBIT B
VAXGEN, INC.
CLINICAL STUDY BUDGET AND PAYMENT SCHEDULE
PROTOCOL VAX004
--------------------------------------------------------------------------------
PROTOCOL NO: VAX004
STUDY CENTER: Name
INVESTIGATOR: Investigator
COMMENCEMENT DATE: , 1999
ANTICIPATED COMPLETION DATE: September 30, 2002
COST PER SUBJECT: $ 3,750.00
ANTICIPATED ENROLLMENT: 150
PROJECTED TOTAL REIMBURSEMENT: $ 562,500.00
BREAKDOWN OF PAYMENTS
I. INITIATION PAYMENT $ 37,500.00
------------------
The Initial Payment shall be made within thirty (30) days, once a signed copy of
the Agreement is returned to VaxGen, all regulatory documents have been received
and approved by VaxGen. The Initial Payment shall be credited against ten (10)
Per Subject Payments.
II. PAYMENT PER SUBJECT (a "Per Subject Payment") $ 3,750.00
------------------
Per Subject Payments shall be made for evaluable, eligible Subjects only. An
evaluable Subject is one for whom 16 CRFs, representing all visits by a Subject
for 36 months, have been completed in accordance with the Protocol, completed
the appropriate study procedures as set forth in the Protocol, and undergone the
evaluations required by the Protocol for assessment of efficacy and safety. An
eligible Subject is one that meets the inclusion/exclusion requirements of the
Protocol, that was enrolled by the Study Center and from whom Informed Consent
has been obtained. Per Subject Payments shall become due for each Subject upon
VaxGen's satisfactory review of all study documentation, including completed
CRFs and close-out audits. A completed CRF is one that is signed by the
Investigator and contains all complete verified information in accordance with
the procedures and scheduled assessments as stated in the Protocol.
Subsequent payments shall be made quarterly, upon VaxGen's receipt and
satisfactory review of completed case report forms. Quarterly payments shall be
determined by the total number of subject
16
17
visits and case report forms received, reviewed and accepted by VaxGen within
the preceding three month period for each quarter ending March 31, June 30,
September 30 and December 31 during the term of this Agreement.
An amount equal to fifteen percent (15%) of all payments made during this
Agreement shall be withheld by VaxGen until all case report forms required to be
completed under the Protocol have been received by VaxGen and all Data
discrepancies have been resolved at the end of the trial. Once resolved, the
final payment is due within (30) days.
In the event that there are less than 16 completed CRFs for a Subject, VaxGen
shall only be obligated to make payment for such Subject on a pro-rated,
completed CRF basis contingent on the date of discontinuation from the Study in
accordance with the Protocol. Each completed CRF for enrolled and randomized
subjects who do not complete all study visits shall be reimbursed at a rate of
$234.38.
For those subjects who sero-convert during the course of the clinical trial,
they will rollover into the study schedule for HIV-1 infected subjects as
identified in Exhibit B-2 of the Protocol. Each completed CRF for enrolled
subjects who rollover into the study schedule for HIV-1 infected subjects will
be reimbursed at a rate of $250.00.
17
